1G. Hegner,G. Faust,F. Freytag,S. Meilenbrock,J. Sullivan,F. Bodin. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide[J] 1997,European Journal of Clinical Pharmacology(3):173～177
2P. Müller,T. Cohen,M. Gasparo,A. Sioufi,A. Bacine-Poon,H. Howald. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects[J] 1994,European Journal of Clinical Pharmacology(3):231～245
7Acourciere Y, Belanger A. Long-term comparison of Valsartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy [ J ]. Kidney Int, 2000,58 (2) :762
8Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease[ J]. J Hypertens, 2000, 18(1) :89-95
9Ohishi M, Takagi T, Ito N, et al. Renal protective effect in hypertensive patients : the high doses of angiotensin Ⅱ receptor blocker (HARB) study [ J ]. Hypertens Res, 2007, 30 ( 12): 1187-1192
10Cornel Issm VA,Fagard RH.Effects of endurance training on blood pressure,blood pressure-regulating mechanisms cardiovascularrisk factors.Hypertension,2005,46(7):667-675.
